Ongoing trials
All Multiple Myeloma patients including smoldering Multiple Myeloma
Targovax: A phase 1/2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed KRAS or NRAS codon 12/13 mutation and high risk smoldering multiple myeloma, or multiple myeloma, and evidence of measurable disease following ≥ 1 line of treatment
Smoldering Multiple Myeloma:
EMN34 (ERASMM): A multi-center, open-label, phase 2 study of elranatamab in patients with high-risk smoldering multiple myeloma
Newly Diagnosed Multiple Myeloma
REMNANT: The Relapse from MRD negativity as indication for treatment (REMNANT) study- A randomized, open label two-part (phase II and III) to assess whether earlier treatment of relapse, based on Measurable Residual Disease (MRD) prolongs progression free and overall survival and improves quality of life for myeloma patients
MajesTEC-7: A phase 3 randomized study comparing teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy
MagnetisMM-7: A phase 3 randomised study comparing elranatamab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma patients
SHIELD: Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma
Dreamm-10: A Phase 3, randomized, open-label study of Belantamab Mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation
MajesTEC-4: A randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Relapsed/Refractory Multiple Myeloma
ACT: Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma
CA057-003: Phase 1b/2a study to evaluate mezigdomide in combination with other treatments in relapsed or refractory multiple myeloma
Impress: A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. Ceritinib is investigated in triple-exposed multiple myeloma patients with high LTK expression
QUINTESSENTIAL-2: A phase 3, randomized study to compare the efficacy and safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T cell therapy, versus standard regimens in adult participants with relapsed or refractory and lenalidomide-exposed multiple myeloma
MagnetisMM-32: A phase 3, open-label study of elranatamab monotherapy versus elotuzumab, pomalidomide, dexamethasone (EPd) or carfilzomib, dexamethasone (Kd) in participants with relapsed/refractory multiple myeloma who received prior anti-CD38 directed therapy
TRIgnite-1: A Phase 1, open-label study to evaluate the safety and anti-myeloma activity of ISB 2001, a BCMAxCD38xCD3-targeting trispecific antibody, in participants with relapsed/refractory multiple myeloma
M24-555: Phase 1/2 study of Etentamig (a BCMAxCD3-targeting bi-specific antibody) in combination with a CELMoD agent for the treatment of patients with relapsed/refractory multiple myeloma